Biogen (NASDAQ: BIIB) and Ocera Therapeutics (NASDAQ:TZYM) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation and analyst recommendations.
Volatility & Risk
Biogen has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500. Comparatively, Ocera Therapeutics has a beta of 2.3, indicating that its stock price is 130% more volatile than the S&P 500.
This is a breakdown of recent ratings and target prices for Biogen and Ocera Therapeutics, as reported by MarketBeat.com.
||Strong Buy Ratings
Biogen presently has a consensus target price of $342.62, indicating a potential upside of 10.36%. Given Biogen’s higher probable upside, research analysts clearly believe Biogen is more favorable than Ocera Therapeutics.
Earnings & Valuation
This table compares Biogen and Ocera Therapeutics’ revenue, earnings per share and valuation.
||Earnings Per Share
Biogen has higher revenue and earnings than Ocera Therapeutics. Ocera Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
87.8% of Biogen shares are held by institutional investors. 0.3% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This table compares Biogen and Ocera Therapeutics’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Biogen beats Ocera Therapeutics on 10 of the 11 factors compared between the two stocks.
Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company’s product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.
About Ocera Therapeutics
Ocera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. It is conducting a randomized, placebo-controlled double blind Phase IIb clinical trial to evaluate the efficacy of intravenous administration of OCR-002 IV formulation in reducing the severity of HE symptoms among HE patients. The Company also conducted a Phase IIa investigator-sponsored trial of OCR-002 in Spain in patients with upper gastrointestinal bleeding associated with liver cirrhosis. It is developing an oral form of OCR-002 to provide continuity of care for HE patients, where the intravenous form is used for hospital-based acute care and the oral form for chronic maintenance care post discharge.
Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.